The pharmacological inhibition of Gal-1 presents a promising strategy for treating cardiovascular diseases, with several small molecules and monoclonal antibodies demonstrating efficacy in preclinical models of atherosclerosis, myocardial infarction, and heart failure [58,60]. The gene discussed is GAL; the disease is myocardial infarction.